Based on the transcript, Ceradyne's Q4 and full-year results show mixed signals. The company achieved record sales but faced delays in military contracts and a reduced 2008 forecast. Management's focus on non-defense growth and strategic expansions indicates potential long-term opportunities. However, the lowered guidance and uncertainties around key defense contracts suggest short-term pressure. The stock is likely to face a negative impact in the next 1-2 weeks due to tempered guidance and defense market uncertainties.

-1